Treatment of cancer using a CD123 chimeric antigen receptor

US11591404B2 · kind B2 · utility

Assignees

• Novartis AG · CH
• The Trustees of the University of Pennsylvania · US

Inventors

• Jennifer Brogdon · Cambridge, US
• Saar Gill · Philadelphia, US
• David Glass · Cambridge, US
• Saad Kenderian · Philadelphia, US
• Andreas Loew · Somerville, US
• Joan Mannick · Cambridge, US
• Michael C. Milone · Cherry Hill, US
• Leon Murphy · Cambridge, US
• David L. Porter · Springfield, US
• Marco Ruella · Ardmore, US
• Yongqiang Wang · Shanghai, CN
• Qilong Wu · Shanghai, CN
• Jiquan Zhang · Shanghai, CN

Key dates

• Filing date: May 27, 2020
• Grant date: Feb 28, 2023
• Expiry date: Sep 24, 2040

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2319/33
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention provides compositions and methods for treating diseases associated with expression of CD123. The invention also relates to chimeric antigen receptor (CAR) specific to CD123, vectors encoding the same, and recombinant cells comprising the CD123 CAR. The invention also includes methods of administering a genetically modified cell expressing a CAR that comprises a CD123 binding domain.